On September 8, BioNTech SE fell 5.08% in regular trading, trading at $98.39/share, with turnover of approximately $47.57 million. The decline was triggered by a notable analyst downgrade from a major investment bank.

BMO Capital Markets downgraded BioNTech SE from Outperform to Market Perform, simultaneously cutting its price target from $128 to $105. The firm cited limited near-term upside potential and an increasingly balanced risk-reward profile as the primary reasons for the revision. According to analyst consensus data, BioNTech SE still carries an average rating of Overweight with a mean price target of $119.05, suggesting BMO's revised view is now below the Street consensus.

The downgrade comes amid a broader challenging backdrop for the company. BioNTech SE previously cautioned that proposed healthcare reforms in Germany could jeopardize future investments in the country, while its most recent quarterly earnings reported an EPS of -$3.03. The company continues to advance its extensive oncology pipeline, including collaborations with Bristol Myers Squibb on pumitamig for advanced renal cell carcinoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)